Skip to content

Clinical Curative Effect Research of Coronary Heart Disease Angina Pectoris Intervened by Lianxia Ningxin Granule Based on the Theory of Heart Leading Blood Pulse-Mind

Clinical Curative Effect Research of Coronary Heart Disease Angina Pectoris Intervened by Lianxia Ningxin Granule Based on the Theory of Heart Leading Blood Pulse-Mind

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16007809
Enrollment
Unknown
Registered
2016-01-21
Start date
2016-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary atherosclerotic heart disease

Interventions

Sponsors

The third affiliated hospital of Beijing traditional Chinese medicine University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: The patients of Chronic stable coronary heart disease angina pectoris, in line with any one of the following situation is included in the study: (1) The patients were diagnosied of coronary heart disease angina pectoris by coronary angiography or coronary CTA; (2) or the patient heve ever been diagnosied of myocardial infarction, recurrence angina pectoris; (3) or the patient have been treated by PCI and CABG postoperative, recurrence angina pectoris; (4) and the patient heve been diagnosied of phlegm heat syndrome.

Exclusion criteria

Exclusion criteria: If patients have any one of the following situation is excluded from the study: (1) The patients with coronary heart disease in acute coronary syndrome (acute myocardial infarction and unstable angina); (2) The patients with high blood pressure more than 24/14.67 KPa (24/14.67 MMHG),and poor control of blood pressure; (3) The patients with cardiac function class III or above; (4) The patients with severe heart rhythm disorders, such as frequent flutter, atrial fibrillation, ectopic beats, frequent ventricular speed, speed, H degree atrioventricular block, etc.; (5) The patients with severe heart disease or other serious disease, such as cardiomyopathy, heart failure, sick sinus syndrome, diabetes (diabetes with peripheral neuropathy), severe liver and kidney dysfunction, chronic obstructive pulmonary disease (asthma); Thyroid function hyperfunction, etc.; (6) The patients with liveror kidney or hematopoietic system serious primary diseases, serious abnormal liver function and renal function, mental disorder; (7) The patients with menopause syndrome or complex cell tumor; (8) The patients older than 80 years old; (9) Other situations that the researchers think discomfort.

Design outcomes

Primary

MeasureTime frame
heart rate;blood pressure;Angina pectoris symptom score;Phlegm fever scale;Seattle Inventory (SAQ);HRV;plasma catecholamine(CA);six-minute walk test;

Countries

China

Contacts

Public ContactLi Ping
pearll2008@126.com+86 13701085215

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026